Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5196283 | 0.91 | F10 (0.71) | F10KLK1 | |
| SCHEMBL6730422 | 0.87 | F10 (0.74) | F10KLK1 | |
| SCHEMBL6737185 | 0.86 | F10 (0.68) | F10KLK1 | |
| SCHEMBL1302499 | 0.83 | F10 (0.68) | F10KLK1 | |
| SCHEMBL6421733 | 0.83 | F10 (0.71) | F10KLK1 | |
| SCHEMBL6930063 | 0.83 | F10 (0.66) | F10KLK1 | |
| SCHEMBL6730994 | 0.83 | F10 (0.61) | F10KLK1 | |
| SCHEMBL8175554 | 0.82 | F10 (0.74) | F10KLK1 | |
| SCHEMBL6781543 | 0.82 | F10 (0.61) | F10KLK1 | |
| Hydrochloric Acid SCHEMBL6730920 | 0.82 | F10 (0.65) | F10KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1528061-A1 | Heterocyclic derivatives which inhibit factor Xa | AstraZeneca AB (SE) | 2005-05-04 | — | — | EP | disclosed |
| US-20040266759-A1 | Heterocyclic derivatives which inhibit factor Xa | ASTRAZENECA AB | 2004-12-30 | — | — | US | disclosed |
| EP-1082321-B1 | HETEROCYCLIC DERIVATIVES WHICH INHIBIT FACTOR XA | ASTRAZENECA AB (SE) | 2004-11-17 | — | — | EP | disclosed |
| US-6753331-B1 | INDOL-2-YLSULPHONYL-4-(4-(HETEROCYCLE)BENZOYL)PIPERAZINE DERIVATIVES AS ANTICOAGULANTS | ASTRAZENECA AB (SE) | 2004-06-22 | — | — | US | disclosed |
| EP-1082321-A1 | HETEROCYCLIC DERIVATIVES WHICH INHIBIT FACTOR XA | AstraZeneca AB (SE) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999057113-A1 | HETEROCYCLIC DERIVATIVES WHICH INHIBIT FACTOR XA | ASTRAZENECA AB (SE) | 1999-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266759-A1 | Heterocyclic derivatives which inhibit factor Xa | F12, TFPI, F2 | F10 9/4885KLK1 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.